Targeting the TGFβ signaling network in human neoplasia

Cancer Cell

Volumn 3, Issue 6, 2003, Pages 531-536

  Dumont, Nancy ^a   Arteaga, Carlos L ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 D11; 2 G7; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AP 12009; BETAGLYCAN; ESTROGEN; HUMAN RECOMBINANT TRANSFORMING BETA RECEPTOR 3; LERDELIMUMAB; LY 364947; METELIMUMAB; NPC 30345; SBI 14352; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 RETROVIRUS; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA2 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2 RETROVIRUS; TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR NEUTRALIZING IMMUNOGLOBULIN G; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; BREAST TUMOR; CACHEXIA; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON ADENOMA; COLON CARCINOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; INTESTINE POLYP; METASTASIS; NEOPLASM; NONHUMAN; ONCOGENE; PANCREAS CANCER; PARACRINE SIGNALING; PLASTICITY; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

FELIS CATUS; UNIDENTIFIED RETROVIRUS;

EID: 0038724672     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00135-1     Document Type: Review

References (50)

1. Ananth S., Knebelmann B., Gruning W., Dhanabal M., Walz G., Stillman I.E., Sukhatme V.P. Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res. 59:1999;2210-2216.
2. Arteaga C.L., Carty-Dugger T., Moses H.L., Hurd S.D., Pietenpol J.A. Transforming growth factor β 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 4:1993;193-201. a.
3. Arteaga C.L., Hurd S.D., Winnier A.R., Johnson M.D., Fendly B.M., Forbes J.T. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest. 92:1993;2569-2576. b.
4. Bakin A.V., Tomlinson A.K., Bhowmick N.A., Moses H.L., Arteaga C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275:2000;36803-36810.
5. Bandyopadhyay A., Zhu Y., Cibull M.L., Bao L., Chen C., Sun L. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res. 59:1999;5041-5046.
6. Bandyopadhyay A., Lopez-Casillas F., Malik S.N., Montiel J.L., Mendoza V., Yang J., Sun L.Z. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 62:2002;4690-4695.
7. Bottinger E.P., Jakubczak J.L., Haines D.C., Bagnall K., Wakefield L.M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12- dimethylbenz-[a]-anthracene. Cancer Res. 57:1997;5564-5570.
8. Cui W., Fowlis D.J., Bryson S., Duffie E., Ireland H., Balmain A., Akhurst R.J. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 86:1996;531-542.
9. Derynck R., Akhurst R.J., Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29:2001;117-129.
10. Dumont N., Arteaga C.L. Transforming growth factor-β and breast cancer. Tumor promoting effects of transforming growth factor-β Breast Cancer Res. 2:2000;125-132.
11. Dumont N., Bakin A.V., Arteaga C.L. Autocrine transforming growth factor-β signaling mediates Smad-independent motility in human cancer cells. J. Biol. Chem. 278:2003;3275-3285.
12. Engle S.J., Hoying J.B., Boivin G.P., Ormsby I., Gartside P.S., Doetschman T. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 59:1999;3379-3386.
13. Gobbi H., Dupont W.D., Simpson J.F., Plummer W.D. Jr., Schuyler P.A., Olson S.J., Arteaga C.L., Page D.L. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl. Cancer Inst. 91:1999;2096-2101.
14. Gohongi T., Fukumura D., Boucher Y., Yun C.O., Soff G.A., Compton C., Todoroki T., Jain R.K. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth. involvement of transforming growth factor β1 Nat. Med. 5:1999;1203-1208.
15. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:2001;1118-1122.
16. Gorska A.E., Joseph H., Derynck R., Moses H.L., Serra R. Dominant-negative interference of the transforming growth factor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ. 9:1998;229-238.
17. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
18. Iglesias M., Frontelo P., Gamallo C., Quintanilla M. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas. Oncogene. 19:2000;4134-4145.
19. Janda E., Lehmann K., Killisch I., Jechlinger M., Herzig M., Downward J., Beug H., Grunert S. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis. dissection of Ras signaling pathways J. Cell Biol. 156:2002;299-313.
20. Kleeff J., Ishiwata T., Maruyama H., Friess H., Truong P., Buchler M.W., Falb D., Korc M. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 18:1999;5363-5372.
21. Kuppner M.C., Hamou M.F., Bodmer S., Fontana A., de Tribolet N. The glioblastoma-derived T-cell suppressor factor/transforming growth factor β2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int. J. Cancer. 42:1988;562-567.
22. Laping N.J., Grygielko E., Mathur A., Butter S., Bomberger J., Tweed C., Martin W., Fornwald J., Lehr R., Harling J.et al. Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity. SB-431542 Mol. Pharmacol. 62:2002;58-64.
23. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B.et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
24. Marzo A.L., Fitzpatrick D.R., Robinson B.W., Scott B. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. 57:1997;3200-3207.
25. Massagué J. TGF-β signal transduction. Annu. Rev. Biochem. 67:1998;753-791.
26. Massagué J., Blain S.W., Lo R.S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 103:2000;295-309.
27. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells. involvement of type I receptors J. Cell Biol. 127:1994;2021-2036.
28. Muraoka R.S., Dumont N., Ritter C.A., Dugger T.C., Brantley D.M., Chen J., Easterly E., Roebuck L.R., Ryan S., Gotwals P.J.et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109:2002;1551-1559.
29. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., Itoh S., Kawabata M., Heldin N.E., Heldin C.H., ten Dijke P. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature. 389:1997;631-635.
30. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., Reichmann E. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10:1996;2462-2477.
31. Oft M., Heider K.H., Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8:1998;1243-1252.
32. Oft M., Akhurst R.J., Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4:2002;487-494.
33. Pierce D.F. Jr., Johnson M.D., Matsui Y., Robinson S.D., Gold L.I., Purchio A.F., Daniel C.W., Hogan B.L., Moses H.L. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Dev. 7:1993;2308-2317.
34. Pierce D.F. Jr., Gorska A.E., Chytil A., Meise K.S., Page D.L., Coffey R.J. Jr., Moses H.L. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci. USA. 92:1995;4254-4258.
35. Rowland-Goldsmith M.A., Maruyama H., Kusama T., Ralli S., Korc M. Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin. Cancer Res. 7:2001;2931-2940.
36. Sawyer J.S., Anderson B.D., Beight D.W., Campbell R.M., Jones M.L., Herron D.K., Lampe J.W., McCowan J.R., McMillen W.T., Mort N.et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J. Med. Chem. in press:2003.
37. Shin I., Bakin A.V., Rodeck U., Brunet A., Arteaga C.L. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol. Biol. Cell. 12:2001;3328-3339.
38. Siriwardena D., Khaw P.T., King A.J., Donaldson M.L., Overton B.M., Migdal C., Cordeiro M.F. Human antitransforming growth factor β(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy. a randomized placebo controlled clinical study Ophthalmology. 109:2002;427-431.
39. Tang B., Bottinger E.P., Jakowlew S.B., Bagnall K.M., Mariano J., Anver M.R., Letterio J.J., Wakefield L.M. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4:1998;802-807.
40. Tsushima H., Ito N., Tamura S., Matsuda Y., Inada M., Yabuuchi I., Imai Y., Nagashima R., Misawa H., Takeda H.et al. Circulating transforming growth factor β1 as a predictor of liver metastasis after resection in colorectal cancer. Clin. Cancer Res. 7:2001;1258-1262.
41. Wagner M., Kleeff J., Friess H., Buchler M.W., Korc M. Enhanced expression of the type II transforming growth factor-β receptor is associated with decreased survival in human pancreatic cancer. Pancreas. 19:1999;370-376.
42. Watanabe T., Wu T.T., Catalano P.J., Ueki T., Satriano R., Haller D.G., Benson A.B. 3rd, Hamilton S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344:2001;1196-1206.
43. Weeks B.H., He W., Olson K.L., Wang X.J. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res. 61:2001;7435-7443.
44. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression with TGF-β inhibitors. Invest. New Drugs. 21:2003;1-12.
45. Wu S.P., Sun L.Z., Willson J.K., Humphrey L., Kerbel R., Brattain M.G. Repression of autocrine transforming growth factor β1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ. 4:1993;115-123.
46. Xu X., Brodie S.G., Yang X., Im Y.H., Parks W.T., Chen L., Zhou Y.X., Weinstein M., Kim S.J., Deng C.X. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene. 19:2000;1868-1874.
47. Yang Y.A., Dukhanina O., Tang B., Mamura M., Letterio J.J., MacGregor J., Patel S.C., Khozin S., Liu Z.Y., Green J.et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109:2002;1607-1615.
48. Zhu Y., Richardson J.A., Parada L.F., Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714.
49. Ziv E., Cauley J., Morin P.A., Saiz R., Browner W.S. Association between the T29→C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women. The study of osteoporotic fractures JAMA. 285:2001;2859-2863.
50. Zugmaier G., Paik S., Wilding G., Knabbe C., Bano M., Lupu R., Deschauer B., Simpson S., Dickson R.B., Lippman M. Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res. 51:1991;3590-3594.